Clinical dilemmas in viral liver disease / edited by, Graham R. Foster, K. Rajender Reddy.

Contributor(s): Foster, Graham R [editor.] | Reddy, K. Rajender [editor.]
Language: English Series: Clinical Dilemmas (UK)Publisher: Hoboken, NJ, USA : Wiley-Blackwell, 2020Edition: Second editionDescription: 1 online resourceContent type: text Media type: computer Carrier type: online resourceISBN: 9781119533399; 9781119533443; 1119533449; 9781119533436; 1119533430Subject(s): Hepatitis, Viral | Hepatitis, Viral -- Diagnosis | Hepatitis, Viral -- Treatment | Liver -- Diseases -- Diagnosis | Liver -- Diseases -- Treatment | Hepatitis, Viral, Human -- diagnosis | Hepatitis, Viral, Human -- therapy | Hepatitis, Chronic -- diagnosis | Hepatitis, Chronic -- therapy | Liver Cirrhosis -- diagnosis | Liver Cirrhosis -- therapy | Diagnostic Techniques, Digestive SystemGenre/Form: Electronic books.DDC classification: 616.3/623 LOC classification: RC848.H43Online resources: Full text is available at Wiley Online Library Click here to view
Contents:
Table of Contents List of Contributors vii Preface xi Part I: Investigating the Liver 1 Noninvasive markers of fibrosis: how reliable are they? 3 Laurent Castera 2 Liver biopsy in chronic viral hepatitis: is there still life left in it? 9 Jaspreet Suri and Michael P. Curry 3 Screening for hepatocellular carcinoma in viral liver disease: any new biomarkers on the horizon? 15 Saroja Bangaru, Jorge A. Marrero, and Amit G. Singal 4 Realistic estimates of hepatitis C virus and hepatitis B virus disease burden 19 Homie Razavi Part II: Today’s Therapies Section 1: HCV 5 Acute hepatitis C: treat immediately or give a chance to spontaneously clear? 29 David E. Kaplan 6 Is ribavirin alive or dead in the current era of HCV therapy? 35 Vijay Prabhakar and Paul Y. Kwo 7 Hepatitis C virus genotype and viral testing, and on‐treatment monitoring: necessary or overkill? 41 Sirina Ekpanyapong and K. Rajender Reddy 8 Treatment of hepatitis C virus in renal disease: can we use all the drugs without additional monitoring? 48 Stanislas Pol 9 Does directly acting antiviral therapy improve quality of life? 54 Daniel M. Forton 10 Morbid obesity and hepatitis C: treat as normal or are there additional issues to consider? 59 María Fernanda Guerra, Javier Ampuero, and Manuel Romero‐Gómez 11 Generic direct‐acting antiviral agents: do they work well? 66 Omar Salim Al Siyabi and Seng‐Gee Lim 12 Impact and management of patients with multiple hepatitis C virus genotypes 74 Peter Ferenci 13 Hepatitis C virus and injecting drug use: what are the challenges? 78 Olav Dalgard 14 Hepatitis B virus reactivation while on hepatitis C virus direct‐acting antiviral therapy: is that a real concern and when is it a concern? 82 Marina Serper 15 Drug–drug interactions with direct‐acting antivirals: when do we need to care? 86 Fiona Marra and David Back 16 Treatment of hepatitis C in children 94 Maureen M. Jonas 17 While direct‐acting antivirals are effective, are there any unique safety considerations? 97 Olivia Pietri, Félix Trottier‐Tellier, and Marc Bourlière 18 Harm reduction strategies to prevent new infections and reinfections among people who inject drugs: how effective are they? 106 Jason Grebely and Marianne Martinello 19 Hepatitis C virus therapy in advanced liver disease: treat or transplant and treat? 112 Chalermrat Bunchorntavakul and K. Rajender Reddy 20 Hepatocellular carcinoma and hepatitis C virus: which should be treated first? 117 Mario U. Mondelli, Andrea Lombardi, and Massimo Colombo 21 Should we incentivize patients to take hepatitis C virus therapy? 122 Ed Gane 22 Treating prisoners with hepatitis C: should we do it and how? 125 Seth Francis‐Graham and William Rosenberg 23 Use of hepatitis C virus‐positive organs for uninfected recipients in the era of effective and safe direct‐acting antivirals: pros and cons 132 Sirina Ekpanyapong and K. Rajender Reddy 24 Is real‐life hepatitis C virus therapy as effective as in clinical trials? 138 Jessica Su and Joseph K. Lim Section 2: HBV, HDV, and HEV 25 Management of acute hepatitis B infection: when should we offer antiviral therapy? 145 Emma Hathorn and David J. Mutimer 26 Rethinking the inactive carrier state: management of patients with low‐replicative HBeAg‐negative chronic hepatitis B and normal liver enzymes 150 María Buti, Mar Riveiro‐Barciela, and Rafael Esteban 27 Hepatitis B e antigen‐positive chronic hepatitis B infection with minimal changes on liver biopsy: what to do next 156 Apostolos Koffas and Patrick T. Kennedy 28 The management of hepatitis B virus in pregnancy 160 Henry L.Y. Chan 29 Treatment of hepatitis B in children 164 Maureen M. Jonas 30 Hepatitis B vaccine failures: how do we handle them? 169 Daniel Shouval 31 The stopping rules in hepatitis B virus therapy: can we provide any guidance? 175 Florian van Bömmel and Thomas Berg 32 Hepatitis C and hepatitis B coinfection 182 Chun‐Jen Liu and Jia‐Horng Kao 33 Chronic hepatitis E virus infection: is it reality or hype and where does it matter? 189 Nassim Kamar and Jacques Izopet 34 Hepatitis E virus vaccines: have they arrived – when, where and for whom? 193 Amit Goel and Rakesh Aggarwal Part III: Clinical Set‐up and the Future 35 Do we need expert hepatitis C virus treaters or are amateur treaters good enough? 203 Shyamasundaran Kottilil and Poonam Mathur 36 Hepatitis C vaccines: how close are we to the promised land? 208 Timothy Donnison, Senthil Chinnakannan, Paola Cicconi, and Eleanor Barnes 37 Elimination of hepatitis C virus in high‐prevalence, low‐income countries: is it feasible? 216 Mahmoud Abdo and Hadeel Gamal Eldeen 38 Hepatitis B virus diagnostics: anything new? 220 Dina Ginzberg, Robert J. Wong, and Robert G. Gish Part IV: Ongoing Controversies 39 Is hepatocellular carcinoma risk impacted favorably or unfavorably by hepatitis C virus therapy with direct‐acting antivirals? 233 Giuseppe Cabibbo, Calogero Cammà, and Antonio Craxì 40 Global elimination of hepatitis C virus by 2030: the optimistic view 238 Gregory J. Dore and Marianne Martinello 41 Global elimination of hepatitis C virus by 2030: the pessimistic view 244 Thomas G. Cotter and Michael Charlton Index 250
Summary: "Viral hepatitis is an extremely complex disease to treat. The medical team involved in the care of patients with viral hepatitis will be faced on a daily basis with clinical challenges. The answers to specific questions are not easily located in the current medical literature: if they are there, they may only be found after extensive searching or the compilation of information from numerous sources. The aim of this book is to provide evidence-based guidance on topical clinical questions and difficulties/dilemmas encountered by the medical team involved in the diagnosis, treatment and management of patients with viral liver disease: the medical team includes the hepatologist/pediatric hepatologist, pathologist, radiologist, transplant surgeon and nurse specialist. This book presents specific and clearly defined topics, in short chapters, selected either because they are of interest in themselves, recent developments or areas of controversy.It will be of particular interest to trainees and fellows in hepatology"-- Provided by publisher.
Tags from this library: No tags from this library for this title. Log in to add tags.
    Average rating: 0.0 (0 votes)
Item type Current location Home library Call number Status Date due Barcode Item holds
EBOOK EBOOK COLLEGE LIBRARY
COLLEGE LIBRARY
616.3623 C6161 2020 (Browse shelf) Available CL-52980
Total holds: 0

Includes bibliographical references and index.

Table of Contents
List of Contributors vii

Preface xi

Part I: Investigating the Liver

1 Noninvasive markers of fibrosis: how reliable are they? 3
Laurent Castera

2 Liver biopsy in chronic viral hepatitis: is there still life left in it? 9
Jaspreet Suri and Michael P. Curry

3 Screening for hepatocellular carcinoma in viral liver disease: any new biomarkers on the horizon? 15
Saroja Bangaru, Jorge A. Marrero, and Amit G. Singal

4 Realistic estimates of hepatitis C virus and hepatitis B virus disease burden 19
Homie Razavi

Part II: Today’s Therapies

Section 1: HCV

5 Acute hepatitis C: treat immediately or give a chance to spontaneously clear? 29
David E. Kaplan

6 Is ribavirin alive or dead in the current era of HCV therapy? 35
Vijay Prabhakar and Paul Y. Kwo

7 Hepatitis C virus genotype and viral testing, and on‐treatment monitoring: necessary or overkill? 41
Sirina Ekpanyapong and K. Rajender Reddy

8 Treatment of hepatitis C virus in renal disease: can we use all the drugs without additional monitoring? 48
Stanislas Pol

9 Does directly acting antiviral therapy improve quality of life? 54
Daniel M. Forton

10 Morbid obesity and hepatitis C: treat as normal or are there additional issues to consider? 59
María Fernanda Guerra, Javier Ampuero, and Manuel Romero‐Gómez

11 Generic direct‐acting antiviral agents: do they work well? 66
Omar Salim Al Siyabi and Seng‐Gee Lim

12 Impact and management of patients with multiple hepatitis C virus genotypes 74
Peter Ferenci

13 Hepatitis C virus and injecting drug use: what are the challenges? 78
Olav Dalgard

14 Hepatitis B virus reactivation while on hepatitis C virus direct‐acting antiviral therapy: is that a real concern and when is it a concern? 82
Marina Serper

15 Drug–drug interactions with direct‐acting antivirals: when do we need to care? 86
Fiona Marra and David Back

16 Treatment of hepatitis C in children 94
Maureen M. Jonas

17 While direct‐acting antivirals are effective, are there any unique safety considerations? 97
Olivia Pietri, Félix Trottier‐Tellier, and Marc Bourlière

18 Harm reduction strategies to prevent new infections and reinfections among people who inject drugs: how effective are they? 106
Jason Grebely and Marianne Martinello

19 Hepatitis C virus therapy in advanced liver disease: treat or transplant and treat? 112
Chalermrat Bunchorntavakul and K. Rajender Reddy

20 Hepatocellular carcinoma and hepatitis C virus: which should be treated first? 117
Mario U. Mondelli, Andrea Lombardi, and Massimo Colombo

21 Should we incentivize patients to take hepatitis C virus therapy? 122
Ed Gane

22 Treating prisoners with hepatitis C: should we do it and how? 125
Seth Francis‐Graham and William Rosenberg

23 Use of hepatitis C virus‐positive organs for uninfected recipients in the era of effective and safe direct‐acting antivirals: pros and cons 132
Sirina Ekpanyapong and K. Rajender Reddy

24 Is real‐life hepatitis C virus therapy as effective as in clinical trials? 138
Jessica Su and Joseph K. Lim

Section 2: HBV, HDV, and HEV

25 Management of acute hepatitis B infection: when should we offer antiviral therapy? 145
Emma Hathorn and David J. Mutimer

26 Rethinking the inactive carrier state: management of patients with low‐replicative HBeAg‐negative chronic hepatitis B and normal liver enzymes 150
María Buti, Mar Riveiro‐Barciela, and Rafael Esteban

27 Hepatitis B e antigen‐positive chronic hepatitis B infection with minimal changes on liver biopsy: what to do next 156
Apostolos Koffas and Patrick T. Kennedy

28 The management of hepatitis B virus in pregnancy 160
Henry L.Y. Chan

29 Treatment of hepatitis B in children 164
Maureen M. Jonas

30 Hepatitis B vaccine failures: how do we handle them? 169
Daniel Shouval

31 The stopping rules in hepatitis B virus therapy: can we provide any guidance? 175
Florian van Bömmel and Thomas Berg

32 Hepatitis C and hepatitis B coinfection 182
Chun‐Jen Liu and Jia‐Horng Kao

33 Chronic hepatitis E virus infection: is it reality or hype and where does it matter? 189
Nassim Kamar and Jacques Izopet

34 Hepatitis E virus vaccines: have they arrived – when, where and for whom? 193
Amit Goel and Rakesh Aggarwal

Part III: Clinical Set‐up and the Future

35 Do we need expert hepatitis C virus treaters or are amateur treaters good enough? 203
Shyamasundaran Kottilil and Poonam Mathur

36 Hepatitis C vaccines: how close are we to the promised land? 208
Timothy Donnison, Senthil Chinnakannan, Paola Cicconi, and Eleanor Barnes

37 Elimination of hepatitis C virus in high‐prevalence, low‐income countries: is it feasible? 216
Mahmoud Abdo and Hadeel Gamal Eldeen

38 Hepatitis B virus diagnostics: anything new? 220
Dina Ginzberg, Robert J. Wong, and Robert G. Gish

Part IV: Ongoing Controversies

39 Is hepatocellular carcinoma risk impacted favorably or unfavorably by hepatitis C virus therapy with direct‐acting antivirals? 233
Giuseppe Cabibbo, Calogero Cammà, and Antonio Craxì

40 Global elimination of hepatitis C virus by 2030: the optimistic view 238
Gregory J. Dore and Marianne Martinello

41 Global elimination of hepatitis C virus by 2030: the pessimistic view 244
Thomas G. Cotter and Michael Charlton

Index 250

"Viral hepatitis is an extremely complex disease to treat. The medical team involved in the care of patients with viral hepatitis will be faced on a daily basis with clinical challenges. The answers to specific questions are not easily located in the current medical literature: if they are there, they may only be found after extensive searching or the compilation of information from numerous sources. The aim of this book is to provide evidence-based guidance on topical clinical questions and difficulties/dilemmas encountered by the medical team involved in the diagnosis, treatment and management of patients with viral liver disease: the medical team includes the hepatologist/pediatric hepatologist, pathologist, radiologist, transplant surgeon and nurse specialist. This book presents specific and clearly defined topics, in short chapters, selected either because they are of interest in themselves, recent developments or areas of controversy.It will be of particular interest to trainees and fellows in hepatology"-- Provided by publisher.

About the Author
Edited by

Graham R. Foster PhD, FRCP, Professor of Hepatology, The Blizard Institute, Barts and The London School of Medicine, Queen Mary University of London, London, UK.

K. Rajender Reddy MD, FACP, FACG, FRCP, FAASLD, Ruimy Family President's Distinguished Professor of Medicine, Professor of Medicine in Surgery, Director of Hepatology, Director of Viral Hepatitis Center, Medical Director of Liver Transplantation, University of Pennsylvania, Philadelphia, PA, USA.

There are no comments for this item.

to post a comment.